

3. Fujiwara A, Komasa N, Minami T. Pectoral nerves (PECS) and intercostal nerve block for cardiac resynchronization therapy device implantation. *Springerplus* 2014;3:409.

4. Munshey F, Ramamurthi RJ, Tsui B. Early experience with PECS 1 block for Port-a-Cath insertion or removal in children at a single institution. *J Clin Anesth* 2018;49:63–4.

Conflicts of interest.—The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Article first published online: January 4, 2019. - Manuscript accepted: December 17, 2018. - Manuscript revised: November 22, 2018. - Manuscript received: September 17, 2018.

(Cite this article as: Piliago C, Longo F, Costa F, Martuscelli M, Claps F, Agrò FE. Are we doing all we can for procedural pain? Evaluation of the efficacy of pectoral nerve block for port catheter positioning. *Minerva Anestesiologica* 2019;85:560-1. DOI: 10.23736/S0375-9393.18.13308-6)

© 2018 EDIZIONI MINERVA MEDICA

Online version at <http://www.minervamedica.it>

Minerva Anestesiologica 2019 May;85(5):561-2

DOI: 10.23736/S0375-9393.18.13395-5

Rapidly fatal neurological and cardiocirculatory failure in a patient recently treated with nefopam

A 65-year-old woman was found unconscious (Glasgow Coma Scale 3/15) and with respiratory failure (gaspings) at the pneumology ward where she had been admitted for chronic obstructive pulmonary disease (COPD) exacerbation. She had a history of psychiatric disorders treated with several psychoactive drugs and a recent traumatic lumbar vertebral fracture requiring the introduction of analgesics. Her recent therapy included: amisulpride 50 mg/day, aripiprazole 15 mg/day, amitriptyline 75 mg/day, mirtazapine 15 mg/day, bupropion 300 mg/day, tramadol 300 mg/day. Oral nefopam was rapidly increased from 30 to 120 mg/day over two days and she received the last dose of 60 mg about five hours after the acute event. At the arrival of the medical intervention team, blood pressure was 90/40 mmHg, heart rhythm was irregular (150/min), respiratory rate <5 breaths/min, and temperature 39.2 °C. After intubation, the patient was transferred to the intensive care unit, where she was found with dilated and poorly reactive pupils, diaphoresis and generalized myoclonic jerks that were only transiently improved after diazepam administration. The EEG (diffuse slowing, 4 Hz) failed to demonstrate epileptic activity. Rectal temperature rose up to 40 °C. Further evolution was characterized by a major hemodynamic instability with variable heart rhythm 70-140

bpm, while electrocardiogram revealed supraventricular tachycardia with a *de-novo* right bundle branch block. Contractility was preserved at echocardiography. Despite cooling measures (including neuromuscular blocking agents), fluid resuscitation and infusion of massive doses of epinephrine and norepinephrine (up to 6 µg/kg/min), the patient died within six hours from refractory shock. Laboratory investigations were poorly relevant at the exception of a mild hyperlactatemia. All the psychoactive drugs were within therapeutic range. Blood cultures remained sterile. Investigation by brain and thoracic computed tomography was also negative. Post-mortem examination failed to reveal any specific lesion.

Serotonin toxicity was suspected. Classically, the recognition of the so-called serotonin syndrome (SS) is based on the triad of cognitive impairment, autonomic dysfunction and abnormalities of neuromuscular function.^{1,2} It is not unusual for signs and symptoms from only one or two of these categories to predominate. The severity of the clinical manifestations appears extremely variable and fatalities are usually related to autonomic disorders with hypotension carrying an unfavorable prognosis. In general, the onset of SS is precipitated by a change in dose of a serotonergic drug or by the recent addition of another serotonergic agent. In our patient, impaired cognition, hyperthermia, myoclonic jerks, diaphoresis and dysautonomia were all consistent with clinical manifestations of serotonin toxicity. Muscle rigidity is frequent in SS, but its absence does not exclude SS especially as neuromuscular blocking agents were early administered to prevent progression of hyperthermia. As serotonin syndrome is often a diagnosis of exclusion, common causes of shock (infectious, cardiogenic, etc.) have to be reasonably ruled out. The patient's chronic treatment included numerous drugs that were associated with the occurrence of serotonin syndrome, either as a single drug therapy or in combination. The only recent change was the introduction of increasing doses of nefopam. Nefopam is a non-opiate potent analgesic whose mechanism of action is not fully understood. Inhibition of catecholamines and serotonin reuptake in the central nervous system has been suggested. Specific *in-vitro* ligand studies revealed that nefopam showed various affinities for serotonergic receptor subtypes with decreasing affinities for 5-HT_{2C}, 5-HT_{2A}, 5-HT₃, 5-HT_{1B}, and 5-HT_{1A} receptor subtypes.^{3,4} Analgesic properties appear related to its action on 5-HT₃ receptors. Few studies have investigated nefopam-induced adverse drug reactions.⁵ Fatalities appear extremely rare; death seems to be related to convulsions and cardiovascular events. In the present observation, the close temporal relationship with the introduction of nefopam, points out the possible responsibility of nefopam in the fatal adverse event. Whether this could be related to serotonergic properties of the drug remains debatable, as there are no laboratory or ancillary tests for SS. The clinicians should be aware of the risks of combining drugs with serotonergic properties.

Jetlir TRUNGU¹, Fatima LAARBAUI²,
Mélodie DECHAMPS², Philippe HANTSON^{1*}

